Clinical Trial Detail

NCT ID NCT03412877
Title Administration of Autologous T-Cells Genetically Engineered to Express T-Cell Receptors Reactive Against Mutated Neoantigens in People With Metastatic Cancer
Recruitment Recruiting
Gender both
Phase Phase II
Variant Requirements No
Sponsors National Cancer Institute (NCI)
Indications

gastrointestinal system cancer

reproductive organ cancer

lung non-small cell carcinoma

ovarian cancer

Advanced Solid Tumor

breast cancer

glioblastoma multiforme

urinary system cancer

Therapies

Aldesleukin + Cyclophosphamide + Fludarabine + iTCR-transduced PBL

Aldesleukin + Cyclophosphamide + Fludarabine + iTCR-transduced PBL + Pembrolizumab

Age Groups: senior adult

No variant requirements are available.